Do you want to read an article? Please log in or register.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Multiple Sclerosis
RECOMMENDED
Related content
Multiple Sclerosis
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
Lancet Neurol
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A, Tolebrutinib Phase 2b Study Group.
doi: 10.1016/S1474-4422(21)00237-4
RECOMMENDED
Multiple Sclerosis
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
Lancet Neurol.
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI, SYNERGY study investigators.
doi: 10.1016/S1474-
Multiple Sclerosis
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Lancet Neurol.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D
doi: 10.1016/S1474-4422
Migraine and HeadacheMultiple Sclerosis
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Lancet Neurol.
Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T
doi: 10.1016/
RECOMMENDED
Multiple Sclerosis
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD, SPI2 investigative teams.
doi: 10.1016/S1474-4422(20)30347-1
Multiple Sclerosis
Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue
Mult Scler.
Fitzgerald KC, Morris B, Soroosh A, Balshi A, Maher D, Kaplin A, Nourbakhsh B
doi: 10.1177/1352458520936226.
Multiple Sclerosis
Tablet App Based Dexterity Training in Multiple Sclerosis (TAD-MS): Research Protocol of a Randomized Controlled Trial
Front Neurol.
van Beek JJW, van Wegen EEH, Bol CD, Rietberg MB, Kamm CP, Vanbellingen T
doi: 10.3389/fneur.2019.00061.
RECOMMENDED
Further Publications Neurology
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol
Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E
doi: 10.1016/S1474-4422(20)30354-9
Multiple Sclerosis
A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis
J Neurol Neurosurg Psychiatry.
Coe S, Cossington J, Collett J, Soundy A, Izadi H, Ovington M, Durkin L, Kirsten M, Clegg M, Cavey A, Wade DT, Palace J, DeLuca GC, Chapman K, Harrison JM, Buckingham E, Dawes H
doi: 10.1136/jnnp-2018-319496.